Group 1 - Emergent BioSolutions Inc. received an order worth up to $21.5 million from the US Department of War for the supply of BioThrax, the only FDA-approved anthrax vaccine [1][2] - Deliveries of BioThrax are expected to occur throughout 2026, with a one-year base period and optional extensions into 2027 and 2028, highlighting the company's ongoing role in US defense against biological threats [2] - The company announced a collaboration with PANTHER to fund the "MpOx Study in Africa," which is testing potential treatments for Mpox, positioning the company in a high-demand area amid ongoing outbreaks [3] Group 2 - Emergent BioSolutions is focused on providing solutions to public health threats, including opioid overdoses, infectious diseases, and biological threats [4]

Group 1 - Letitia James has accused Robert Kramer of selling his shares in Emergent before revealing contamination issues related to the production of the Covid-19 vaccine [1]

PresentationFirst, you're going to hear a presentation from the company, and then we're going to have some Q&A. So for those of you in the room, if you want to ask a question, just raise your hand, someone will bring you a microphone for the webcast. And alternatively, for those listening online, you can submit questions via the portal, and I can read them off the iPad up here. So with that out of the way, let me pass it over to Emergent's CEO, Joe Papa.Great. Welcome, everyone. My name is Jess Fye. I'm a b ...

Emergent BioSolutions FY Conference Summary Company Overview - **Company Name**: Emergent BioSolutions (NYSE:EBS) - **Industry**: Biodefense and Opioid Overdose Treatment - **Established**: 25 years ago - **Mission**: Protect and save lives through biodefense products and opioid overdose treatments [3][4] Core Business Areas 1. **Biodefense Products**: - Portfolio includes 11 products targeting serious threats like smallpox, anthrax, botulism, and Ebola [4][11] - Collaborates with U.S. and global governments for vaccine and therapeutic development [4][12] 2. **Opioid Overdose Treatment**: - Market leader with Narcan for opioid overdose treatment [4][20] - Focus on increasing access to Narcan, aiming for widespread availability [21][22] Turnaround Plan - **Timeline**: Multi-year plan initiated in 2024 - **Phases**: 1. **Stabilization** (2024-2025): Streamlined operations, divested $150 million in assets, reduced operating expenses by $250 million, and improved Adjusted EBITDA from negative in 2023 to $183 million in 2024 [7][30] 2. **Turnaround** (2025-2026): Focus on growth investments, both organic and inorganic [9][10] 3. **Transformation** (2026 and beyond): Aim for a sustainable and profitable company [10][32] Financial Performance - **Debt Reduction**: Total debt reduced by $275 million since 2023, with net leverage down from 9.9 times to approximately 2 times [8][30] - **Revenue Trends**: Revenue decreased due to divestitures but Adjusted EBITDA margin improved from 19% in 2024 to 33% in 2025 [29][30] - **Future Guidance**: Projected Adjusted EBITDA for 2025 between $195-$210 million [7] Market Dynamics - **Geographic Diversification**: Revenue from outside the U.S. increased from 15% to 34% [19] - **Bipartisan Support**: Strong political backing for biodefense initiatives and opioid overdose solutions [15][16] Product Innovations - **Narcan Backpack Kit**: Recently approved by the FDA to enhance accessibility for potential users [22][23] - **Partnerships**: Collaborations with RocketVax for rapid vaccine development and Hikma for Kloxxado, a higher dose naloxone product [24][25] Pipeline and Future Opportunities - **Key Products**: Ebanga for Ebola, TEMBEXA for smallpox, and Raxibacumab for anthrax [26][28] - **Clinical Trials**: New trials for TEMBEXA in mpox treatment initiated [28] - **Growth Investments**: Focus on expanding international reach and developing new products [31][46] Challenges and Competitive Landscape - **Naloxone Market**: Anticipated mid-single-digit growth in overall naloxone unit volume, with Narcan expected to maintain market leadership [36][37] - **Funding Opportunities**: Potential $50 billion from opioid litigation settlements to support naloxone distribution [41] Conclusion - Emergent BioSolutions is on track with its turnaround plan, focusing on growth and innovation while maintaining a commitment to patient safety and quality [32][33]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Combating Public Health Threats for Communities Around the World Company Overview 44th Annual J.P. Morgan Healthcare Conference Joe Papa President and Chief Executive Officer January 14, 2026 1 1 Safe Harbor Statement/Trademarks This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements, other than statements of historical fact, including statements regarding the future performance of the Company or any of our ...

Core Insights - Emergent BioSolutions has received FDA approval for a new carrying case for its NARCAN® Nasal Spray, aimed at enhancing accessibility and encouraging individuals to carry the life-saving medication during opioid emergencies [1][3] Product Development - The new packaging for NARCAN® Nasal Spray includes two blister packs and a Quick Start Guide, designed to be compact, discreet, and durable [1] - The carrying case aims to integrate seamlessly into daily life, addressing the low carry rate of the medication, which is currently at only 10% among the general consumer population [3] Consumer Insights - A survey conducted by Emergent revealed that 74% of consumers prefer a discreet carrying case over standard packaging, with this preference rising to 81% among college students, a high-risk group for opioid misuse [2] Market Impact - Since its prescription launch in 2016, over 85 million doses of NARCAN® have been distributed across the U.S. and Canada, indicating significant market penetration and demand for opioid overdose reversal solutions [4]

Core Insights - Emergent BioSolutions, Inc. has made a voluntary prepayment of $100 million on its term loan facility, reflecting a strong cash position and financial flexibility for future strategic initiatives [1][2] - The company's gross debt has been reduced by $275 million since 2023, totaling $593 million as of September 30, 2025, marking a 32% decline in total debt as part of its multi-year transformation plan [2] Financial Position - The prepayment of $100 million was executed using cash on hand, indicating a proactive approach to managing debt [1] - The reduction in gross debt to $593 million demonstrates significant progress in improving the company's financial health [2] Strategic Initiatives - The company aims to enhance its financial flexibility and position itself for long-term stability and growth through ongoing transformation efforts [2] - Emergent BioSolutions is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, highlighting its commitment to transparency and engagement with investors [3]

Core Viewpoint - Emergent BioSolutions has received a delivery order valued at up to $21.5 million from the U.S. Department of War to supply BioThrax in 2026 under an existing IDIQ contract [1] Group 1: Contract Details - The order includes a one-year base period with two additional option periods for 2027 and 2028 [2] - Deliveries under this order will take place in 2026 [2] Group 2: Product Information - BioThrax is indicated for the active immunization against disease caused by Bacillus anthracis in individuals aged 18 to 65 [3] - The vaccine is approved for both pre-exposure and post-exposure prophylaxis of anthrax [3] Group 3: Company Mission - Emergent BioSolutions aims to protect and save lives, focusing on health threats such as anthrax, smallpox, and Ebola [6]

Core Insights - Emergent BioSolutions has announced a collaboration with PANTHER to support the Africa CDC-led 'MpOx Study in Africa' (MOSA), aimed at researching treatments for mpox, a virus lacking dedicated antiviral therapy [1] - The MOSA study, launched in 2024, is a double-blind, platform-adaptive clinical trial evaluating treatment options for mpox across multiple African countries, initially funded by the European Union and Africa CDC [1] - An independent data and safety monitoring board (DSMB) reviewed the safety data of MOSA in December 2025, recommending the continuation of the trial with no safety concerns identified [2] Company and Industry Overview - Emergent BioSolutions focuses on protecting public health by delivering life-saving solutions for various health threats, including mpox [5] - PANTHER is an African-led pandemic preparedness platform that aims to enhance regional response to emerging infectious diseases, particularly in Africa [6] - The Africa CDC is a public health agency of the African Union, supporting member states in strengthening health systems and improving disease surveillance and emergency response [8] Study Progress and Impact - The MOSA study represents a significant step in generating evidence for mpox treatment and enhancing Africa's capacity to respond to health threats, with over 61,383 confirmed cases and 296 deaths reported across 32 countries since 2024 [4] - The study will expand to new countries, including Uganda, as part of its efforts to reach the next milestone in patient enrollment [3]